Dongwha Pharm.Co.,Ltd (KRX:000020)
South Korea · Delayed Price · Currency is KRW 5,830.00
-100.00 (-1.69%)
At close: Apr 2, 2026
Dongwha Pharm.Co.,Ltd Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 496,394 | 464,875 | 361,109 | 340,426 | 293,018 |
Other Revenue | - | - | - | -0 | - |
| 496,394 | 464,875 | 361,109 | 340,426 | 293,018 | |
Revenue Growth (YoY) | 6.78% | 28.73% | 6.08% | 16.18% | 7.70% |
Cost of Revenue | 277,847 | 250,617 | 170,693 | 159,436 | 143,671 |
Gross Profit | 218,547 | 214,258 | 190,416 | 180,990 | 149,347 |
Selling, General & Admin | 176,639 | 165,146 | 142,338 | 125,515 | 103,217 |
Research & Development | 25,701 | 23,599 | 21,548 | 19,285 | 17,338 |
Amortization of Goodwill & Intangibles | 3,404 | 2,976 | 1,139 | 1,327 | 1,491 |
Other Operating Expenses | 2,407 | 2,362 | 2,291 | 1,993 | 1,808 |
Operating Expenses | 218,791 | 200,847 | 171,750 | 151,075 | 126,848 |
Operating Income | -243.25 | 13,411 | 18,666 | 29,915 | 22,499 |
Interest Expense | -4,513 | -2,152 | -308.01 | -370 | -383.11 |
Interest & Investment Income | 2,045 | 2,491 | 6,683 | 2,493 | 1,744 |
Earnings From Equity Investments | - | -219.37 | 2,420 | -2,269 | -410.4 |
Currency Exchange Gain (Loss) | -27.28 | -460.25 | 377.78 | 31.87 | 687.36 |
Other Non Operating Income (Expenses) | -577.91 | 566.8 | 145.65 | 527.55 | 630.9 |
EBT Excluding Unusual Items | -3,317 | 13,637 | 27,985 | 30,328 | 24,768 |
Gain (Loss) on Sale of Investments | 454.76 | -6,435 | 9,434 | -4,506 | 1,801 |
Gain (Loss) on Sale of Assets | 9,012 | 21.1 | 28.76 | 741.89 | 169.46 |
Asset Writedown | -146.59 | -321.16 | -491.98 | -3,478 | -316.08 |
Other Unusual Items | - | - | - | - | 105.41 |
Pretax Income | 6,003 | 6,902 | 36,956 | 23,086 | 26,527 |
Income Tax Expense | 2,161 | 4,756 | 8,719 | 1,494 | 6,944 |
Earnings From Continuing Operations | 3,842 | 2,146 | 28,237 | 21,591 | 19,583 |
Minority Interest in Earnings | 4,844 | 3,417 | -798.76 | -1,208 | -1,712 |
Net Income | 8,686 | 5,563 | 27,438 | 20,383 | 17,870 |
Net Income to Common | 8,686 | 5,563 | 27,438 | 20,383 | 17,870 |
Net Income Growth | 56.13% | -79.72% | 34.61% | 14.06% | -37.31% |
Shares Outstanding (Basic) | 28 | 28 | 28 | 28 | 28 |
Shares Outstanding (Diluted) | 28 | 28 | 28 | 28 | 28 |
Shares Change (YoY) | 0.26% | -0.03% | 0.02% | 0.16% | 0.05% |
EPS (Basic) | 313.00 | 201.00 | 991.07 | 736.42 | 646.68 |
EPS (Diluted) | 313.00 | 201.00 | 991.07 | 736.42 | 646.68 |
EPS Growth | 55.72% | -79.72% | 34.58% | 13.88% | -37.37% |
Free Cash Flow | -38,442 | -40,689 | 4,626 | 10,792 | 14,087 |
Free Cash Flow Per Share | -1385.24 | -1470.08 | 167.09 | 389.91 | 509.78 |
Dividend Per Share | - | - | 180.000 | 180.000 | 180.000 |
Gross Margin | 44.03% | 46.09% | 52.73% | 53.17% | 50.97% |
Operating Margin | -0.05% | 2.89% | 5.17% | 8.79% | 7.68% |
Profit Margin | 1.75% | 1.20% | 7.60% | 5.99% | 6.10% |
Free Cash Flow Margin | -7.74% | -8.75% | 1.28% | 3.17% | 4.81% |
EBITDA | 21,722 | 33,080 | 32,562 | 42,424 | 34,591 |
EBITDA Margin | 4.38% | 7.12% | 9.02% | 12.46% | 11.80% |
D&A For EBITDA | 21,965 | 19,669 | 13,896 | 12,509 | 12,093 |
EBIT | -243.25 | 13,411 | 18,666 | 29,915 | 22,499 |
EBIT Margin | -0.05% | 2.89% | 5.17% | 8.79% | 7.68% |
Effective Tax Rate | 35.99% | 68.91% | 23.59% | 6.47% | 26.18% |
Advertising Expenses | 45,058 | 48,368 | 41,140 | 34,455 | 29,889 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.